Circulating Tumor Reactive KIR+CD8+ T cells Suppress Anti-Tumor Immunity in Patients with Melanoma.
Journal
Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035
Informations de publication
Date de publication:
28 Feb 2024
28 Feb 2024
Historique:
pubmed:
11
3
2024
medline:
11
3
2024
entrez:
11
3
2024
Statut:
epublish
Résumé
Effective anti-tumor immunity is largely driven by cytotoxic CD8
Identifiants
pubmed: 38464315
doi: 10.21203/rs.3.rs-3956671/v1
pmc: PMC10925449
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NLM NIH HHS
ID : T15 LM007056
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA233414
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA227473
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA269286
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI039671
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA121974
Pays : United States
Organisme : NIH HHS
ID : S10 OD030363
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016359
Pays : United States
Déclaration de conflit d'intérêts
DAH has received research funding from Bristol-Myers Squibb, Novartis, Sanofi, and Genentech. He has been a consultant for Bayer Pharmaceuticals, Repertoire Inc, Bristol Myers Squibb, Compass Therapeutics, EMD Serono, Genentech, Juno therapeutics, Novartis Pharmaceuticals, Proclara Biosciences, Sage Therapeutics, and Sanofi Genzyme. HMK has received institutional research grants from Bristol Myers Squibb, Merck, and Apexigen and financial support from Bristol Myers Squibb, Iovance, Chemocentryx, Signatero, Gigagen, GI Reviewers, Pliant Therapeutics, Esai, Wherewolf, and Invox. CN, SH, AJC, JK, and FJO are employees and/or stockholders of Repertoire Immune Medicines. SH, FJO, and JK are employees of Repertoire Immune Medicines (Switzerland) AG, formerly Tepthera Ltd. All other authors report no competing interests.